

This offering document (the “**Offering Document**”) constitutes an offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities and to those persons to whom they may be lawfully offered for sale. This Offering Document is not, and under no circumstances is to be construed as, a prospectus or advertisement or a public offering of these securities.

No securities regulatory authority or regulator has assessed the merits of these securities or reviewed this document. Any representation to the contrary is an offence. This offering may not be suitable for you and you should only invest in it if you are willing to risk the loss of your entire investment. In making this investment decision, you should seek the advice of a registered dealer.

These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**1933 Act**”), or any state securities laws. Accordingly, these securities may not be offered, sold or delivered within the United States of America (as such term is defined in Regulation S under the 1933 Act, the “**United States**”) except pursuant to an exemption from the registration requirements of the 1933 Act and applicable state securities laws. This Offering Document does not constitute an offer to sell or a solicitation of an offer to buy any of these securities within the United States.

OFFERING DOCUMENT UNDER THE LISTED ISSUER FINANCING EXEMPTION

New Issue

November 18, 2024

WILLOW BIOSCIENCES INC.

The logo for Willow Biosciences Inc. features the word "willow" in a lowercase, bold, sans-serif font. The letter "i" has a distinctive dot that is a solid black circle. The "o"s are also solid black circles, and the "l" is a simple vertical bar. The overall style is clean and modern.

Raise: \$800,000.00 - \$2,001,340.96
Securities Issuable: 10,000,000 - 25,016,762 Units

What are we offering?

Offering: Willow Biosciences Inc. (“**Willow**” or the “**Company**”) is hereby offering for sale to eligible investors a minimum of 10,000,000 units (“**Units**”) and a maximum of 25,016,762 Units of the Company at a price of \$0.08 per Unit for minimum aggregate gross proceeds of \$800,000.00 (the “**Minimum Offering**”) and maximum aggregate gross proceeds of up to \$2,001,340.96 (the “**Maximum Offering**”), pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – *Prospectus Exemptions* (“**NI 45-106**”).

Each Unit is comprised of one (1) common share in the capital of the Company (each, a “**Common Share**”) and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a “**Warrant**”). Each Warrant will entitle the holder thereof to acquire one (1) additional Common Share (each, a “**Warrant Share**”) at an exercise price of \$0.11 per Warrant Share for a period of 36 months from the closing of the Offering, subject to accelerated expiry in the event the volume-weighted average closing price of the Common Shares on the Toronto Stock Exchange (the “**TSX**”) is equal to or exceeds \$0.14 for ten (10) consecutive trading days. Each Common Share, including any Warrant Share issued upon the exercise of a Warrant, entitles the holder thereof to one vote at meetings of shareholders. The holders of Common Shares are entitled to receive dividends as and when declared by the board of directors of the Company (the “**Board**”) out of monies properly applicable to the payment of dividends, in such amount and in such form as the Board may from time to time determine. The Warrants will be subject to adjustment as to the number of Warrant Shares issuable upon the exercise of the Warrants and/or the exercise price per Warrant Share upon the occurrence of certain customary events. No fractional Warrant Shares will be issuable to any

holder of Warrants upon the exercise thereof, and no cash or other consideration will be paid in lieu of fractional Warrant Shares. The holding of Warrants will not make the holder thereof a shareholder of the Company and holders of Warrants will not have any voting or pre-emptive rights or any other rights of a holder of Common Shares.

Offering Price: \$0.08 per Unit (the “**Offering Price**”).

The Offering Price was determined by the Company with reference to the prevailing market price of the Common Shares of the Company and other factors.

Offering Amount: Maximum: 25,016,762 Units for aggregate gross proceeds of up to \$2,001,340.96

Minimum: 10,000,000 Units for aggregate gross proceeds of \$800,000.00

Closing Date: It is expected that the completion of the sale of the Units pursuant to the Offering will take place on such date or dates as may be decided by the Company, and, in any event, on or before January 2, 2025, being the date that is 45 days from the date of this Offering Document (the “**Closing Date**”). The Offering may close in more than one closing.

Exchange: The Common Shares of Willow are listed and posted for trading on the TSX under the trading symbol “**WLLW**” and on the OTCQB® under the trading symbol “**CANSF**”.

Closing Price: On November 15, 2024, being the most recent trading day before the date hereof, the closing price of the Common Shares on the TSX and OTCQB®, was \$0.095 and US\$0.0665, respectively.

Currency: All references in this Offering Document to “dollars”, “C\$” or “\$” are to Canadian dollars, unless otherwise stated. References to “US\$” are to United States dollars.

Willow is conducting a listed issuer financing under section 5A.2 of NI 45-106. In connection with this Offering, the Company represents that each of the following is true:

- **Willow has active operations and its principal asset is not cash, cash equivalents or its exchange listing.**
- **Willow has filed all periodic and timely disclosure documents that it is required to have filed.**
- **The total dollar amount of this Offering, in combination with the dollar amount of all other offerings made under the listed issuer financing exemption in the 12 months immediately before the date of this Offering Document, will not exceed \$5,000,000.**
- **Willow will not close this Offering unless it reasonably believes it has raised sufficient funds to meet its business objectives and liquidity requirements for a period of 12 months following the distribution.**
- **Willow will not allocate the available funds from this Offering to an acquisition that is a significant acquisition or restructuring transaction under securities law or to any other transaction for which the Company seeks security holder approval.**

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this Offering Document constitute forward-looking statements. All forward-looking statements are based on the Company’s belief and assumptions based on information available at the time the assumption was made. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. By their nature, such forward-looking statements involve known and unknown risks,

uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this Offering Document should not be unduly relied upon. For more information on the Company and the risks and challenges of its business, investors should review the Company's condensed interim consolidated financial statements for the three and nine month period ended September 30, 2024 and 2023, management's discussion and analysis of financial condition and results of operations for the three and nine months ended September 30, 2024, and annual information form for the year ended December 31, 2023, all of which are available on the Company's SEDAR+ profile at www.sedarplus.ca.

In particular, this Offering Document and the documents incorporated by reference herein contain forward-looking statements pertaining to, but not limited to, the following: the Company's ability to complete the Offering and anticipated timing and proceeds thereof; the Company's anticipated use of proceeds; the Company's ability to continue as a going concern; expectations as to the Company's business strategy and future operations and milestones; the ability of the Company to execute on its strategy and the anticipated benefits of such strategy; the use of available funds and proceeds set forth herein; the business plan of the Company, generally, including research at the Company's Mountain View, California research facility and production at the Company's partner locations; the expected benefits of yeast-based fermentation over plant-based extraction and traditional synthesis; the ability of the Company to accommodate new programs and to expand capabilities, including the expansion of the Company's portfolio of functional ingredients; licensing risks and expectations with respect to renewal and/or extension of the Company's licences; the Company's financial position and future prospects; negative operating cash flow; reliance on third parties and partners and expected benefits from strategic relationships; expected operating costs, general and administrative costs, costs of services and other costs and expenses; ability to meet current and future obligations; ability to obtain financing on acceptable terms or at all; change in laws, regulations and guidelines; expectations with respect to the cannabinoid market and market risks; future liquidity and financial capacity; and the competitive and business strategies of the Company.

With respect to forward-looking statements contained in this Offering Document, the Company has made assumptions regarding, among other things: success of the Company's business strategy, including research milestones and commercialization, partnerships and other strategic activities; success of the Company's research programs concerning its fermentation technology and biosynthetic production of functional ingredients; success of the Company's commercialization efforts, including negotiations with potential customers and suppliers; success and impact of strategic relationships and partnerships; cost reductions and operating efficiencies created by the Company's functional ingredients and its yeast-based ingredient production platform; impact of increasing competition; the successful development of the Company's GLP-1 and opioid antagonist API programs (as such terms are defined herein); timing and amount of capital expenditures; future operating costs; reliance on key inputs; success of quality control systems; ability to obtain and protect intellectual property; product liability; government regulations, including future legislative and regulatory developments applicable to the Company's products and partnered products, and the impact thereof of the Company's business strategy; the ability of the Company to obtain and maintain applicable licences and approvals, and timing for receipt thereof; the demand and market size potential of the synthetic ingredients industry and other industries relating to the Company's products and partnered products; the legislative and regulatory environments of the jurisdictions where the Company carries on business; the ability of the Company to enter into additional business development arrangements and commercial agreements; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; the ability of the Company to obtain and retain qualified staff, services, supplies and equipment in a timely and cost-efficient manner; the success of the Company's strategic partnerships and customer relationships, including the development of future strategic partnerships and customer relationships; the financial strength of the Company and of its strategic partners, including Kalsec® Inc. ("**Kalsec**"); the successful implementation of the Company's commercialization and production strategy, generally; conditions in general economic and financial markets; and the Company's ability to obtain additional financing on satisfactory terms.

Actual results could differ materially from those anticipated in these forward-looking statements as a result of the material risk factors set forth below, elsewhere in this Offering Document including: risks relating to

public health crises; risks related to geopolitical factors and wars; success of the operations, including research objectives, plans and milestones of the Company; success and continuation of strategic relationships; the ability of the Company to execute its business strategy; legislative and regulatory environments of the jurisdictions where the Company carries on business or has operations; the ability to obtain and maintain required approvals and licences; federal, state, provincial and municipal government regulation applicable to the Company's products and partnered products, changes thereto and uncertainty in respect thereof; the impact of inflation on costs; actions taken by governmental authorities, including increases in taxes and changes in government regulations; the impact of competition and the competitive response to the Company's business strategy; risks of industries related to the Company's products and partnered products, such as regulatory risks and increasing competition; timing and amount of capital and other expenditures; the effect of any future litigation proceedings on the Company's business; cyber-security issues; and other factors. The Company has included this summary of assumptions and risks related to forward-looking statements provided in this Offering Document in order to provide investors with a more complete perspective on the Company's current and future operations and such information may not be appropriate for other purposes. The reader is cautioned that such assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect.

The risk factors described herein should not be construed as exhaustive. The forward-looking statement disclosure contained in this Offering Document is expressly qualified by this cautionary statement. These forward-looking statements are made as of the date of this Offering Document. Unless required by law, the Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SUMMARY DESCRIPTION OF BUSINESS

What is our business?

Willow is a synthetic biology company focused on the development of biobased processes for production of ingredients, including those for consumer care, health and wellness, food & beverage, and pharmaceuticals. The Company engineers organisms such as yeast to produce plant, animal, and petrochemical-derived ingredients through precision fermentation. These processes are more sustainable, secure, and cost-effective than traditional extraction or chemical synthesis routes and typically provide final product in higher purity.

Willow combines three development pillars: (i) state-of-the-art rapid strain engineering technologies, (ii) fermentation & downstream process development, and (iii) an established manufacturing network in order to efficiently execute its development of synthetic biology enabled commercial fermentation processes. Willow's strain engineering technologies include proprietary genomic databases for novel gene discovery, an AI guided enzyme evolution platform, and genome engineering platform for multiple production hosts. These technologies provide the performance enzymes and strains for additional fermentation and downstream process optimization for scaling and implementation at a commercial scale within the Company's production network.

Willow leverages the expertise of world-renowned scientists located in a state-of-the-art research facility in Sunnyvale, California, through which the team exploits a wide variety of high throughput screening technologies to identify and combine beneficial genetic elements that enhance the performance of its enzymes and strains. This facility includes state-of-the-art automation equipment, analytical instrumentation, and bench-scale fermentation and downstream chemical development capabilities combined with large scale bioinformatics and data handling systems to rapidly evaluate high volumes of data and results. The research team includes several key personnel focused on enzyme and strain engineering, high throughput screening, fermentation, and chemical process development.

More detailed information regarding the business of the Company, its operations and its assets can be accessed on the Company's SEDAR+ profile at www.sedarplus.ca or on its website at www.willowbio.com.

Recent Developments

On January 16, 2024, Willow announced a new collaboration with Enterin, Inc. ("**Enterin**"), a clinical stage biopharmaceutical innovator, to develop a new sustainable manufacturing route to their key intermediates and active pharmaceutical ingredients ("**APIs**"). Enterin is focused on development of groundbreaking therapeutics for treatment of neurodegenerative diseases including Parkinson's and Alzheimer's disease. The initial feasibility program consists of research and development of a biobased pathway, followed by additional optimization and advanced development towards implementation at commercial scale if the feasibility program is successful.

On January 31, 2024, Willow announced a new program with a leading API manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally. This API is a key ingredient in an over-the-counter (OTC) medicine that is part of a multi-billion dollar segment. The API manufacturer recognized the need to employ more sustainable methods to manufacture its APIs with reduced cost and less waste. Willow's expertise is being sought in developing and scaling a manufacturing process for this key ingredient. The new partnership program focuses on optimization of an existing commercial biomanufacturing process for improved performance at scale.

On February 20, 2024 and February 29, 2024, Willow announced multiple strategic investments (the "**Kalsec Investments**") from Kalsec, a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of a large-volume, high value natural ingredient for savory food applications. The investments were in the form of private placements into Willow and resulted in the investment of an aggregate of US\$200,000 into the Company. For additional details, please refer to "*Use of Available Funds - How have we used the other funds we have raised in the past 12 months?*" below.

Pursuant to the Kalsec Investments, the Company issued an aggregate of 1,359,856 units (each, a "**February Unit**") at a subscription price of C\$0.10 per February Unit, and 1,153,131 February Units at a subscription price of C\$0.12 per February Unit. Each February Unit consists of one (1) Common Share and one-half of one (1/2) Common Share purchase warrant (each whole warrant, a "**February Warrant**"). Each February Warrant issued on February 20, 2024, entitles the holder thereof to purchase one (1) Common Share at a price of C\$0.14 per Common Share until February 20, 2025, subject to certain exceptions. Each February Warrant issued on February 29, 2024, entitles the holder thereof to purchase one (1) Common Share at a price of C\$0.16 per Common Share until March 1, 2025, subject to certain exceptions.

On May 28, 2024, Willow announced a multi-product development and licensing partnership (the "**Partnership**") with Laurus Labs ("**Laurus**"), a leading research-driven pharmaceutical and biotechnology company that serves global pharmaceutical companies and offers contract development and manufacturing organization services. Through this partnership, Willow will leverage its AI-driven technology platform and extensive experience in enzyme, strain, and process engineering to deliver biobased processes for high-value APIs with existing markets, including Willow's BioOxi™-based corticosteroid processes, for large scale manufacturing, sales, and distribution at Laurus. Willow and Laurus expect these first programs to reach commercial manufacture in 2025. Under the terms of the Partnership, Willow expects to earn significant annual revenues in research & development, over \$4 million in its first year, and royalties. Upon commercialization of the APIs, Willow will receive an annual royalty based on worldwide sales.

On July 18, 2024, Willow announced the completion of its brokered private placement offering of 16,397,365 units (each, a "**July Unit**") at a price of \$0.10 per July Unit for aggregate gross proceeds to the Company of \$1,639,736.50 (the "**July Offering**"). Each July Unit was comprised of one (1) Common Share and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a "**July Warrant**"). Each July Warrant entitles the holder thereof to acquire one (1) Common Share at an exercise price of \$0.13 per Common Share for a period of 36 months from the closing of the Offering, subject to accelerated expiry in the event the volume-weighted average closing price of the Common Shares on the TSX is equal to or exceeds \$0.17 for ten (10) consecutive trading days. The Offering was conducted by Independent Trading Group (ITG) Inc., who acted as lead agent and sole bookrunner on a "best efforts" basis. ITG received a cash commission of \$86,992.10 and was issued 869,921 non-transferable broker warrants ("**Broker Warrants**"). Each Broker Warrant entitles the holder thereof to purchase one (1) July Unit for a period of

36 months from closing of the July Offering. The Broker Warrants, and the Common Shares and July Warrants underlying the Broker Warrants, are subject to a statutory hold period of four months and one day pursuant to applicable “accredited investor” exemptions under NI 45-106.

On August 7, 2024, Willow announced that it signed a new fully funded strain engineering program with an innovative Ag-Biotech company in the biopesticides sector that is expected to generate over \$2 million in research and development (“R&D”) revenue in 2024 and 2025. The program is on track and has already achieved the first set of R&D milestones.

On September 5, 2024, Willow announced the signing of a commercial license and royalty agreement with Kalsec. Through this commercial license and royalty agreement, Willow expects to receive milestone payments for the first pilot and industrial batches followed by tiered royalty payments on net worldwide sales after launch. Willow expects R&D to be completed later this year or early next year and scaling to start in 2025.

On September 18, 2024, Willow announced a second program with the API manufacturer, to develop a more sustainable, cost-effective manufacturing route for a large volume ingredient used in a therapeutic with a global market in excess of \$1 billion.

On November 7, 2024, Willow announced a new partnered program for a high value ingredient from its internal portfolio with a global ingredient manufacturer to fully develop, scale, and commercialize. Under the terms of the program, if successful, Willow expects to receive payments for R&D followed by a tiered profit share for 15 years after launch. The research program is expected to take 12 months to complete, with near-term payments for R&D to Willow of up to \$1.3 million, should certain performance targets be met through development.

On November 18, 2024, concurrent with the announcement of the Offering, Willow announced that it has commenced work on two new internal programs to replace the prior internal programs which were partnered on May 28, 2024 and November 7, 2024 with Laurus and a global ingredient manufacturer, respectively. The new programs include the development of (a) an innovative biobased process to produce glucagon-like peptide-1 (“GLP-1”) receptor agonists that are the active pharmaceutical ingredients (“APIs”) in medications such as Wegovy® and Zepbound®, and (b) a BioOxi™-based process to produce opioid antagonist APIs, for medications such as Naloxone, which is used to reverse or reduce the effects of opioids. Both developed processes are expected to provide the APIs with significantly less waste and reduced costs.

Material Facts

There are no material facts about the securities being distributed that have not been disclosed in this Offering Document or in any other document filed by the Company in the 12 months preceding the date of this Offering Document.

What are the business objectives that we expect to accomplish using the available funds?

The Company intends to use the net proceeds from the Offering, assuming the Maximum Offering, towards working capital requirements and general corporate purposes and to accelerate development of two high priority programs in the Company’s existing pipeline for future partnering. For more information about these programs, please refer to “*Summary Description of Our Business*” above and “*Use of Available Funds*” below. If the Company is not able to complete the Maximum Offering, assuming the Minimum Offering, Willow intends to use the net proceeds from the Offering working capital requirements and general corporate purposes. Please refer to “*Use of Available Funds*” below. Other than the success of this Offering, there are no significant events which must occur in order to accomplish these business objectives.

USE OF AVAILABLE FUNDS

What will our available funds be upon the closing of the Offering?

The Company's available funds following completion of the Maximum Offering is estimated to be \$1,736,247.09, assuming the Offering is fully subscribed. The minimum to be raised under the Offering is \$800,000.00.

		Assuming Minimum Offering	Assuming Maximum Offering ⁽¹⁾
A	Amount to be raised by this offering	\$ 800,000.00	\$ 2,001,340.96
B	Selling Commissions and Fees ⁽²⁾	\$ (56,000.00)	\$ (140,093.87)
C	Estimated offering costs (e.g., legal, accounting, audit)	\$ (75,000.00)	\$ (75,000.00)
D	Net proceeds of offering D = A – (B + C)	\$ 669,000.00	\$ 1,786,247.09
E	Working capital as at most recent month end (deficiency)	\$ (50,000.00)	\$ (50,000.00)
F	Additional sources of funding	--	--
G	Total available funds G = D + E + F	\$ 619,000.00	\$ 1,736,247.09

Notes:

(1) Assuming the Offering is fully subscribed.

(2) Assuming commissions paid on an Offering to finders, as applicable, at the maximum rate of commission payable of 7.0%. For additional details, please refer to "Fees and Commissions" below.

How will we use the available funds?

The Company intends to use the net proceeds from this Offering as summarized below.

Description of intended use of available funds listed in order of priority		Assuming Minimum Offering	Assuming Maximum Offering
Working capital requirements and general corporate purposes		\$ 619,000.00	\$ 702,207.09
Research and development of new GLP-1 internal program for future partnership	Feasibility phase	--	\$ 258,510.00
	Preliminary Optimization Phase	--	\$ 258,510.00
Research and development of new opioid antagonist APIs internal program for future partnership	Feasibility phase	--	\$ 258,510.00
	Preliminary Optimization Phase	--	\$ 258,510.00
Total:		\$ 619,000.00	\$ 1,736,247.09

The above noted allocation represents the Company's intentions with respect to its use of net proceeds from the Offering based on current knowledge, planning and expectations of management of the Company. However, actual use of funds may differ from the estimates set forth above. There may be circumstances

where for sound business reasons, the Company reallocates the use of available funds. Such uses will not include a significant acquisition, a restructuring transaction, or any transaction requiring approval of the Company's security holders. There can be no assurance that the Company will receive sufficient net proceeds from the Offering to accomplish some or all of the objectives set out above.

The Company intends to use the proceeds of the Offering towards working capital requirements and general corporate purposes and to accelerate development of two high priority programs in the Company's existing pipeline for future partnering. The programs include (a) the development of an innovative biobased process to produce GLP-1 receptor agonists that are the APIs in medications such as Wegovy® and Zepbound®, and (b) the development of a BioOxi™-based process to produce opioid antagonist APIs, for medications such as Naloxone, which is used to reverse or reduce the effects of opioids. Both developed processes are expected to provide the APIs with significantly less waste and reduced costs. The Company has been in discussions with potential partners for both programs; however, management believes that negotiated terms under the partnerships would be more beneficial for the Company, if the programs are partially de-risked in house prior to partnering.

If the Maximum Offering is raised, management believes that a full proof of concept phase that includes preliminary optimization to produce small quantities of key targets could be completed for both programs; however, full proof of concept work could be scaled back to feasibility in high throughput based on the funds available and a lesser amount of research work would still be highly beneficial to negotiations for both programs. Full proof of concept would involve a feasibility phase followed by a preliminary enzyme, strain, and process optimization phase to produce small, non-commercial quantities of the desired molecules in the Company's lab. Less than full proof of concept could include program planning, identifying key enzymes for the process, and demonstrating activity of key enzymes in the feasibility phase for making the desired compounds or closely related analogs in high throughput. All R&D will be completed in-house by the Company. Once the Company has completed the preliminary optimization phases of the programs, if successful, the Company anticipates signing partnership agreements for the programs, where the partner will fund the remainder of the optimization phase. The partner would then be responsible for scale-up, manufacturing, regulatory and sales and marketing, which could take anywhere from 12 to 36 months, depending on a number of factors which are largely beyond the Company's control. The feasibility phases are expected to run concurrently for six months, followed by the preliminary optimization phases which will run concurrently for six months.

The minimum amount to be raised under the Offering is \$800,000.00. In the event the aggregate gross proceeds raised under the Offering fall short of the Maximum Offering, the Company intends to first apply net proceeds towards working capital requirements and general corporate purposes, after which it intends to deploy capital towards the feasibility phase of GLP-1 program, followed by the feasibility program for the opioid antagonist APIs program (after which it would seek to complete the preliminary optimization phase for the GLP-1 program followed by the opioid antagonist APIs program).

The most recent audited annual financial statements and interim financial report of the Company included a going-concern note. The Company has not achieved profitable operations, has accumulated losses since inception and expects to incur further losses in the development of its business, which may cast doubt on the Company's ability to continue as a going concern. The Offering is intended to permit the Company to continue to develop its business operations, and is not expected to affect the decision to include a going concern note in the next annual financial statements of the Company.

How have we used the other funds we have raised in the past 12 months?

The following table sets out the disclosure the Company previously made about how it would use available funds or proceeds from any financing in the past 12 months, an explanation of any variances, and the impact of the variances, if any, on the Company's ability to achieve its business objectives and milestones.

Date	Offering	Disclosed Use of Proceeds	Variance	Impact of variance on Willow's ability to achieve business objectives / milestones
Feb 20, 2024	Non-brokered private placement offering of units of Willow for aggregate gross proceeds of approximately C\$134,662 (US\$100,000) ⁽¹⁾	Commercialization and development of Willow's pipeline of products, including natural food ingredients, working capital, and general corporate purposes	As disclosed	Not applicable
Feb 29, 2024	Non-brokered private placement offering of units of Willow for aggregate gross proceeds of approximately C\$134,916 (US\$100,000) ⁽²⁾	Commercialization and development of Willow's pipeline of products, including natural food ingredients, working capital, and general corporate purposes	As disclosed	Not applicable
July 18, 2024	Brokered private placement offering of units of Willow for aggregate gross proceeds of approximately C\$1,639,736 (US\$1,175,598) ⁽³⁾	Commercialization and development of Willow's pipeline of products, including natural food ingredients, working capital, and general corporate purposes	As disclosed	Not applicable

Notes:

- (1) On January 31, 2024, the Company announced a collaboration with global ingredient manufacturer to develop a more cost-effective, sustainable process for a large volume API. On February 20, 2024, the Company announced a strategic investment from Kalsec in the amount of US\$100,000, with a commitment to contribute an additional US\$100,000 subject to the completion of an operational milestone by Willow to develop a strain that meets certain performance criteria. The initial investment involved the issuance of 1,359,856 Units at a subscription price of \$0.10 per Unit, each Unit comprising of one (1) Common Share and one-half of one (1/2) February Warrant. Each whole February Warrant issued on this date, entitles the holder thereof to purchase one (1) Common Share at a price of \$0.14 until February 20, 2025; provided that if, at any time prior to the expiry date of the February Warrants, the 20-day volume weighted average of the closing price of the Common Shares on the TSX, or other principal exchange on which the Common Shares are listed, is greater than \$0.18, the Company may accelerate the expiry date of the warrants to the date that is 20 days following the date of the notice of such acceleration.
- (2) On February 29, 2024, Willow announced that the milestone was achieved and Kalsec was issued an additional 1,153,131 February Units at a subscription price of \$0.12 per February Unit, each unit comprising of one (1) Common Share and one-half of one (1/2) February Warrant. The February Warrants issued on this date were issued with an exercise price of \$0.16, an expiration date of March 1, 2025, and similar acceleration provisions as set out in (2) above, but triggered at \$0.21 rather than \$0.18.
- (3) On July 18, 2024, Willow announced that it closed a brokered private placement offering of 16,397,365 July Units at a price of \$0.10 per July Unit for aggregate gross proceeds to the Company of \$1,639,736, each July Unit comprising of one (1) Common Share and one-half of one (1/2) July Warrant. Please see "Summary Description of Business – Recent Developments" for more details.

FEES AND COMMISSIONS

Who are the dealers or finders that we have engaged in connection with this Offering, if any, and what are their fees?

The Company has not engaged any dealers or finders in connection with this Offering. However, Willow may pay finders fees to investment dealers and eligible finders (each, a "Finder") in respect of subscribers introduced by such Finder. The Company will pay to each Finder, on the Closing Date, a cash commission of up to 7.0% of the gross proceeds raised in respect of the Offering from subscribers introduced by such Finder. The Company may also issue such number of warrants to the Finder's (each, a "Finder Warrant") that is up to 7% of the number of Common Shares sold pursuant to this Offering in respect of the subscribers introduced by the Finder. Each Finder Warrant will entitle the holder thereof to acquire one additional Unit of the Company at a price of \$0.08 per Unit for a period of three (3) years from the Closing Date.

PURCHASER'S RIGHTS

Rights of Action in the Event of a Misrepresentation

If there is a misrepresentation in this offering document, you have a right:

- (a) to rescind your purchase of these securities with Willow, or
- (b) to damages against Willow and may, in certain jurisdictions, have a statutory right to damages from other persons.

These rights are available to you whether or not you relied on the misrepresentation. However, there are various circumstances that limit your rights. In particular, your rights might be limited if you knew of the misrepresentation when you purchased the securities.

If you intend to rely on the rights described in paragraph (a) or (b) above, you must do so within strict time limitations.

You should refer to any applicable provisions of the securities legislation of your province or territory for the particulars of these rights or consult with a legal adviser.

ADDITIONAL INFORMATION

Where can you find more information about us?

Securityholders can access Willow's continuous disclosure filings on SEDAR+ at www.sedarplus.ca and may find additional information on our website at www.willowbio.com.

Purchasers should read this Offering Document and consult their own professional advisors to assess the income tax, legal, risk factors and other aspects of their investment of the Units.

CERTIFICATE OF THE COMPANY

Dated: November 18, 2024

This Offering Document, together with any document filed under Canadian securities legislation on or after November 18, 2023, contains disclosure of all material facts about the securities being distributed and does not contain a misrepresentation.

(signed) "Chris Savile"

Chris Savile
President and Chief Executive Officer

(signed) "Travis Doupe"

Travis Doupe
Chief Financial Officer